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AbstrAct
Objective  We aimed to investigate whether 
preoperative serum neutrophil gelatinase-associated 
lipocalin (sNGALpre-op) predicted postoperative acute 
kidney injury (AKI) during hospitalisation and 1-year 
cardiovascular and all-cause mortality following adult 
cardiac surgery.
Methods  This study was a post hoc analysis of the 
Effect of Remote Ischemic Preconditioning on Clinical 
Outcomes in Patient Undergoing Coronary Artery Bypass 
Graft Surgery trial involving adult patients undergoing 
coronary artery bypass graft. Postoperative AKI within 
72 hours was defined using the International Kidney 
Disease: Improving Global Outcomes classification.
results 1371 out of 1612 patients had data on 
sNGALpre-op. The overall 1-year cardiovascular and 
all-cause mortality was 5.2% (71/1371) and 7.7% 
(105/1371), respectively. There was an observed 
increase in the incidence of AKI from the first to the 
third tertile of sNGALpre-op (30.5%, 41.5% and 45.9%, 
respectively, p<0.001). There was also an increase in 
both cardiovascular and all-cause mortality from the 
first to the third tertile of sNGALpre-op, linear trend test 
with adjusted p=0.018 and p=0.013, respectively. The 
adjusted HRs for those in the second and third tertiles 
of sNGALpre-op compared with the first tertile were 1.60 
(95% CI 0.78 to 3.25) and 2.22 (95% CI 1.13 to 4.35) 
for cardiovascular mortality, and 1.25 (95% CI 0.71 
to 2.22) and 1.91 (95% CI 1.13 to 3.25) for all-cause 
mortality at 1 year.
conclusion  In a cohort of high-risk adult patients 
undergoing cardiac surgery, there was an increase in 
postoperative AKI and 1-year mortality from the first to 
the third tertile of preoperative serum NGAL. Those in 
the last tertile (>220 ng/L) had an estimated twofold 
increase risk of cardiovascular and all-cause mortality at 
1 year.
clinical trial registration NCT101247545; Post-
results.
IntrOductIOn
Acute kidney injury (AKI) occurs in up to 30%1 2 of 
adult patients undergoing cardiac surgery, and its 
presence is associated with worse short-term and 
long-term morbidity and mortality.3–5 Even mild to 
moderate increases in serum creatinine following 
cardiac surgery are associated with higher 30-day 
mortality.6 7 Around a fifth of patients with AKI 
will go on to require renal replacement therapy,8 
and this subgroup has the worst prognosis with 
in-hospital mortality rates up to 60%.9 The devel-
opment of AKI is multifactorial, and the under-
lying mechanisms remain unclear, although acute 
tubular necrosis is assumed to be the predominant 
pathology.10 Although several tools have been 
developed to predict the development of AKI prior 
to cardiac surgery, they have been predominantly 
designed to predict severe AKI requiring dialysis.2 
More work remains to be done to improve the 
identification of those at risk of even milder grades 
of AKI prior to cardiac surgery.2
Neutrophil gelatinase-associated lipocalin 
(NGAL) belongs to the lipocalin family and is 
produced predominantly by the liver and white 
blood cells.11 It is released excessively in the blood 
pool and in the urine after injury to the kidney 
tubules.12 NGAL has previously been termed the 
‘troponin-like’ biomarker to detect AKI,13 but after 
promising results in children undergoing cardiac 
surgery,14 it has not performed as well for the early 
detection of AKI in adults.15 This can be partly 
explained by the fact that NGAL is not specific for 
the kidney injury, as it can also be released during 
sepsis, inflammation and acute exacerbations of 
chronic illnesses, and therefore it remains a research 
tool.14 Most recently, preoperative plasma NGAL 
has been shown to be independently associated with 
3-year mortality following adult cardiac surgery.16 
There are some conflicting reports on whether 
preoperative plasma NGAL can predict postoper-
ative AKI,17 18 but those studies were underpow-
ered. Therefore, we aimed to investigate whether 
preoperative serum NGAL (sNGALpre-op) predicted 
both postoperative AKI during hospitalisation and 
1-year cardiovascular and all-cause mortality in 
adults undergoing cardiac surgery.
MethOds
The current study was a post hoc analysis of the Effect 
of Remote Ischemic Preconditioning on Clinical 
Outcomes in Patient Undergoing Coronary Artery 
Bypass Graft Surgery (ERICCA) (NCT01247545), 
the trial design and results of which have been 
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previously published.19 20 In brief, 1612 patients were prospec-
tively recruited in this multicentre, randomised controlled trial 
between April 2011 and March 2014 but only those with data 
on sNGALpre-op were included in this analysis (n=1371). The 
inclusion criteria were adults aged >18 years of age and with an 
additive European System for Cardiac Operative Risk Evaluation 
(EuroSCORE)  ≥5  (high  risk),  undergoing  on-pump  coronary 
artery bypass grafting (CABG) with or without valve surgery, 
with blood cardioplegia. Those with an estimated glomerular 
filtration rate (eGFR) <30 mL/min/1.73 m2 were excluded. 
They were randomised to remote ischaemic conditioning (RIC) 
or sham preconditioning. The clinical endpoints collected were 
cardiovascular death and all-cause mortality at 1 year, non-fatal 
myocardial infarction, coronary revascularisation or stroke at 
1 year and AKI within 72 hours followingsurgery as defined by 
the International Kidney Disease: Improving Global Outcomes 
classification (KDIGO).21 There was no difference in the inci-
dence of AKI between those who were randomised to RIC or 
sham. Serum NGAL was measured from blood collected in 
serum-separating tubes preoperatively using CircuLex NGAL/
Lipocalin 2 ELISA. The study was approved by the National 
Health Service Research Ethics Committee, and all patients 
provided informed written consent.
AKI within 72 hours was graded as none, 1, 2, 3 as per the 
KDIGO criteria as follows: grade 1: serum creatinine 1.5–1.9 
times baseline or an increase in serum creatinine ≥26.5 μmol/L; 
grade 2: serum creatinine 2.0–2.9 times baseline; and grade 3: 
serum creatinine 3.0 times baseline or increase in serum creat-
inine  to  ≥353.6  μmol/L  or  initiation  of  renal  replacement 
therapy. The primary outcomes of interest were any AKI grade 
during hospitalisation and cardiovascular and all-cause mortality 
at 1 year.
statistical analysis
Statistical analysis was performed using SPSS V.23. sNGALpre-op 
was analysed as tertiles. Continuous data were expressed as 
means and SD or medians and (first quartile–third quartile), and 
categorical data were reported as frequencies and percentages. 
Unadjusted associations of the tertiles of sNGALpre-op with other 
baseline and procedure variables were performed using one-way 
analysis of variance or Kruskal-Wallis test where appropriate. 
Logistic regression analysis was performed to assess whether 
sNGALpre-op was an independent predictor any grade of AKI (as a 
binary outcome), after adjusting for known preoperative predic-
tors of AKI (age, gender, diabetes mellitus, hypertension, periph-
eral vascular disease (PVD), previous CABG, type of surgery 
planned, use of intra-aortic balloon pump, baseline eGFR, 
baseline left ventricular ejection fraction (LVEF) category and 
preoperative high sensitivity troponin T).2 22 This analysis was 
performed using tertiles of sNGALpre-op, as previously done,
16 to 
allow findings to be more easily translated to the clinical setting. 
Kaplan-Meier curves were used to assess survival at 1 year per 
tertile. The primary analysis for the cumulative incidence of 
cardiovascular and all-cause mortality at 1 year was performed 
using Cox proportional hazard (with censoring of data to the date 
of occurrence of the primary endpoint, lost to follow-up, with-
drawal from the study or at 1 year), and the HRs were computed 
with 95% CI after adjusting for the factors that were present in 
both EuroSCORE II23 and the Society of Thoracic Surgeon (STS) 
score24 that were available from our cohort (namely age, gender, 
eGFR, PVD, previous stroke, previous CABG, baseline LVEF 
category, diabetes mellitus, use of intra-aortic balloon pump, type 
of surgery planned and preoperative high sensitivity troponin T).
results
Out of 1612 patients recruited in the ERICCA trial, 1371 
patients had sNGALpre-op measured. These patients had a mean 
age of 76.0±6.6 years and 27.5% were female. As expected, 
they were in the high-risk category for cardiac surgery with a 
median additive EuroSCORE of 6 (5–7). Further details of the 
baseline characteristics of these 1371 patients per tertile are 
provided in table 1. The overall all-cause mortality and cardio-
vascular mortality was 7.7% (105/1371) and 5.2% (71/1371), 
respectively. AKI data were available in 97% (1330/1371) of 
patients. AKI during the initial hospitalisation occurred in 
39.6% of patients (31.2% AKI grade 1). The median sNGALpre-op 
was 175 (117–257) ng/L and range of 27–3171 ng/L. sNGALpre-op 
was divided into three groups according to tertiles <135 ng/L, 
135–<220 ng/L and ≥220 ng/L. There was no difference in the 
prevalence of diabetes mellitus, hypertension, dyslipidaemia and 
vascular disease among the three tertiles as shown in table 1. 
Furthermore, there was no difference in the type of surgery or 
duration of the cardiopulmonary bypass and cross-clamp times. 
However, patients in the higher tertiles were more likely to be 
older, of the male gender, have higher baseline creatinine and 
eGFR and spend longer time on intensive care unit and in 
hospital. The cardiovascular and all-cause mortality at 1 year per 
tertile and per the presence or absence of AKI are summarised 
in table 2. 
 snGAlpre-op and AKI
On a per-tertile basis, there was an increase in the incidence of 
AKI with increasing tertile of sNGALpre-op from 30.5% in the 
first tertile, 41.5% in the second tertile and 45.9% in the third 
tertile. Using the first tertile of sNGALpre-op as reference, multi-
variable analysis shown that the second tertile of sNGALpre-op had 
an OR of 1.69 (95% CI 1.23 to 2.30), and the third tertile of 
sNGALpre-op had an OR of 1.53 (95% CI 1.12 to 2.10), p=0.009 
for linear trend test, to predict AKI, after adjusting for known 
preoperative predictors of AKI.
Receiver operating characteristic (ROC) curve analysis showed 
that sNGALpre-op was a predictor of AKI, but the c-statistic was 
only 0.57 (95% CI 0.54 to 0.61). The c-statistic improved to 
0.69 (95% CI 0.66 to 0.73) (p<0.001 for ROC curves compar-
ison) when age, gender, diabetes mellitus, hypertension, PVD, 
previous CABG, type of surgery planned, use of intra-aortic 
balloon pump, baseline eGFR, baseline ejection fraction and 
baseline high sensitivity troponin T were included in the model 
together with tertiles of sNGALpre-op as shown in figure 1.
AKI and mortality
Patients with AKI had a higher mortality at 1 year with an all-cause 
mortality rate of 12.1% versus 4.1% (table 2), when compared 
with those without AKI with an adjusted HR (adjusted for the 
above EuroSCORE II and STS-derived preoperative predictors 
of mortality) of 2.67 (95% CI 1.72 to 4.13), adjusted p<0.001 
from the Cox regression analysis. Those with AKI also had worse 
cardiovascular mortality at 1 year with a mortality rate of 7.8% 
versus 2.7%, when compared with those without AKI, with an 
adjusted HR of 2.88 (95% CI 1.67 to 4.98), adjusted p<0.001 
from the Cox regression analysis.
snGAlpre-op and mortality
After a follow-up of 12 months, 5.5% of patients in the first 
tertile died, compared with 7.0% in the second tertile and 10.5% 
of the patients in the third tertile as summarised in table 2. There 
was an increase in both cardiovascular and all-cause mortality 
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from the first to the third tertile of sNGALpre-op, linear trend test 
with adjusted p=0.018 and p=0.013, respectively. With sNGAL-
pre-op in the first tertile as the reference, the adjusted HR (adjusted 
for the above EuroSCORE II and STS-derived preoperative 
predictors of mortality) for those in the second and third tertiles 
of sNGALpre-op were 1.60 (95% CI 0.78 to 3.25) and 2.22 (95% 
CI 1.13 to 4.35) for cardiovascular mortality, and 1.25 (95% CI 
0.71 to 2.22) and 1.91 (95% CI 1.13 to 3.25) for all-cause 
mortality at 1 year. Figure 2 shows the Kaplan-Meier curves for 
1-year all-cause mortality according to tertiles of sNGALpre-op.
dIscussIOn
The major findings of this study of high-risk patients under-
going cardiac surgery were as follows: (1) preoperative serum 
levels of NGAL predicted postoperative AKI, after accounting 
for preoperative clinical parameters (age, gender, diabetes 
mellitus, hypertension, PVD, previous CABG, type of surgery 
planned, use of intra-aortic balloon pump, baseline eGFR, base-
line ejection fraction and baseline high sensitivity troponin T), 
with the performance of sNGALpre-op to predict AKI improving 
when  these  clinical  parameters  were  included  in  the  model; 
(2) tertiles of sNGALpre-op were associated with mortality after 
adjusting for confounders, with those in the third tertile having 
a twofold increase in the hazard for cardiovascular and all-cause 
mortality; (3) the overall incidence of postoperative AKI in this 
cohort was 39.6% and was as high as 45.9% for those in the 
third tertile of sNGALpre-op;  (4)  the presence of AKI was asso-
ciated with mortality, and in our cohort, there was more than 
table 1 Characteristics of patients according to tertiles of sNGALpre-op
n=1371
snGAlpre-op
p Value
First tertile
<135 ng/l
(n=457)
second tertile
135 –<220 ng/l (n=456)
third tertile
>220 ng/l (n=458)
Age/years 75.4±7.0 76.1±6.1 76.6±6.6 0.03
Male (n (%)) 302 (66.2) 342 (75.3) 345 (75.8) 0.001
Additive EuroSCORE 6 (5–7) 6 (5–7) 6 (5–8) 0.03
BMI/kg/m2 27.2±4.5 27.8±4.5 27.7±4.4 0.08
Current smoker (n (%)) 26 (5.7) 28 (6.2) 24 (5.3) 0.45
Diabetes mellitus (n (%)) 112 (24.6) 119 (26.2) 124 (27.3) 0.65
Dyslipidaemia (n (%)) 321 (70.4) 331 (72.9) 316 (69.5) 0.50
Hypertension (n (%)) 345 (75.7) 340 (74.9) 353 (77.6) 0.62
Previous MI (n (%)) 166 (36.4) 189 (41.6) 197 (43.3) 0.09
Atrial fibrillation (n (%)) 70 (15.4) 71 (15.6) 82 (18.0) 0.49
PVD (n (%)) 40 (8.8) 32 (7.0) 37 (8.1) 0.63
Stroke 51 (11.2) 53 (11.7) 51 (11.2) 0.97
LVEF category (n (%)) 0.55
Good 300 (68.8) 296 (67.6) 276 (63.6)
Moderate 89 (20.4) 93 (21.2) 103 (23.7)
Poor 47 (10.8) 49 (11.2) 55 (12.7)
Baseline creatinine/µmol/L 83 (73–97) 91 (76–108) 95 (80–118) <0.001
eGFR at baseline/mL/min/1.73 m2 75 (62–90) 71 (59–85) 67 (53–82) <0.001
Cardiopulmonary bypass time/hour 1.75 (1.39–2.20) 1.72 (1.33–2.23) 1.77 (1.35–2.35) 0.34
Cross-clamp time/hour 1.17 (0.80–1.55) 1.12 (0.78–1.57) 1.15 (0.83–1.63) 0.26
CABG only (n (%)) 229 (50.2) 243 (53.3) 228 (50.1) 0.55
CABG+valve surgery (n (%)) 227 (49.8) 213 (46.7) 227 (49.9)
Length of ITU stay 2 (1–4) 3 (1–5) 3 (1–5) <0.001
Length of hospital stay 9 (7–14) 10 (7–16) 12 (8–21) <0.001
AKI (any) (n (%)) 135 (30.5) 186 (41.5) 206 (45.9) <0.001
PMI 112 (24.5) 102 (22.4) 118 (25.8) 0.48
Stroke 11 (2.4) 5 (1.1) 7 (1.5) 0.29
Revascularisation 1 (0.2) 3 (0.7) 2 (0.4) 0.60
AKI, acute kidney injury; BMI, body mass index; CABG, coronary artery bypass graft surgery; eGFR, estimated glomerular filtration rate; EuroSCORE, European System for Cardiac 
Operative Risk Evaluation; ITU, intensive care unit; LVEF, left ventricular ejection fraction; MI, myocardial infarction; PMI, perioperative myocardial infarction; PVD, peripheral 
vascular disease; RIC, remote ischaemic conditioning; sNGALpre-op, preoperative serum neutrophil gelatinase-associated lipocalin.
table 2 One-year cardiovascular and all-cause mortality rates per tertiles of sNGALpre-op and per presence or absence of AKI
First tertile
<135 ng/l
(n=457)
second tertile
135 –<220 ng/l 
n=456
third tertile
>220 ng/l n=458 Adjusted p value
no AKI
(n=803)
AKI
(n=527) Adjusted p value
1-year cardiovascular 
mortality
3.5% (16) 5.3% (24) 6.8% (31) 0.018 2.7% (22) 7.8% (41) <0.001
1-year all-cause mortality 5.5% (25) 7.0% (32) 10.5% (48) 0.013 4.1% (33) 12.1% (64) <0.001
AKI, acute kidney injury; sNGALpre-op, preoperative serum neutrophil gelatinase-associated lipocalin.
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twofold increase in both cardiovascular and all-cause mortality 
at 1 year.
The performance of the model to predict AKI was improved 
when clinical parameters were included in addition to sNGAL-
pre-op, but the c-statistic was only increased to 0.69. Other risk 
scores to predict AKI have had c-statistics ranging between 0.72 
and 0.84, but most of them were designed to predict worse 
grades of AKI.2 Therefore, Huen et al2 recently concluded that 
more studies are required to develop risk models to predict 
milder forms of AKI after cardiac surgery in a systematic review 
of existing risk scores. However, our study included high-risk 
patients  with  EuroSCORE  ≥5 only  and  whether  by  applying 
the same approach of using sNGALpre-op with clinical parameters 
to predict any grades of AKI would yield a higher diagnostic 
performance warrants further investigation.
Postoperative urinary NGAL25 in contrast to postoper-
ative plasma NGAL16 has been shown to be associated with 
all-cause 3-year mortality. Whether pNGALpre-op could predict 
AKI and mortality has also been investigated. Haase-Fielitz et 
al17 found no difference in preoperative serum NGAL between 
those who developed AKI when compared with those who did 
not. However, this study only included 100 patients and did 
not have mortality data. However, Doi et al18 showed that 
preoperative plasma NGAL was an independent risk factor 
for postoperative AKI in 146 patients. A larger study of 
1191 patients showed that preoperative plasma NGAL was 
a predictor of 3-year mortality, but the relationship between 
NGAL and AKI was not assessed.16 In the general population, 
baseline plasma NGAL has also been shown to be associated 
with 10-year cardiovascular mortality.26 In a cohort of commu-
nity-dwellers with a mean age of 70 years, plasma NGAL was 
a significant predictor of mortality, independent of traditional 
risk factors and renal function.27 We have shown in a larger 
cohort of high-risk patients that sNGALpre-op was a predictor of 
both AKI following cardiac surgery, as well as a predictor of 
1-year cardiovascular and all-cause mortality, after adjusting 
for known preoperative predictors of AKI. Therefore, sNGAL-
pre-op could complement existing tools to risk-stratify patients 
prior to cardiac surgery.
AKI has typically been reported to occur in up to 30%1 2 of 
patients undergoing adult cardiac surgery, but the incidence of 
AKI in our cohort was higher at 39.6%. This may be explained 
by the inclusion of patients with an additive EuroSCORE 
of ≥5 and therefore representative of the incidence of AKI in 
a high-risk cohort.
limitations
Our cohort may not be representative of the wider popula-
tion of patients undergoing CABG surgery as these patients 
were included in a randomised controlled trial. There are 
currently no established cut-off values as shown by the study 
by Moledina et al,16 which used cut-off values of 155 ng/L and 
251 ng/L for the tertiles and we used 130 ng/L and 220 ng/L. 
Although intraoperative factors play a role in the development 
of postoperative AKI, we only looked at preoperative factors 
as the aim of this study was to assess the ability of sNGALpre-op 
to identify those at higher risk of AKI and mortality prior to 
surgery. Ten per cent of the cases had missing data when it 
came to performing the analysis for the adjusted models. We 
did not specifically collect data on sepsis or exacerbation of 
chronic illness prior to surgery, which are known confounders 
for elevated NGAL levels. However, these patients were 
Figure 1 ROC curves of sNGALpre-op in tertiles and the preoperative 
multivariable model to predict AKI. AKI, acute kidney injury; AUC, 
area under the curve; ROC, receiver operating characteristic; sNGALpre-
op, preoperative serum neutrophil gelatinase-associated lipocalin.
Figure 2 Kaplan-Meier curves for 1-year all-cause mortality according 
to tertiles of sNGALpre-op. sNGALpre-op, preoperative serum neutrophil 
gelatinase-associated lipocalin.
Key messages
What is already known about this subject?
The development of acute kidney injury following adult cardiac 
surgery is associated with short-term and long-term morbidity 
and mortality.
What are the new findings?
Preoperative serum neutrophil gelatinase-associated lipocalin 
was an independent predictor of postoperative acute kidney 
injury and 1-year mortality.
how might these results change the focus of research or 
clinical practice?
Preoperative serum neutrophil gelatinase-associated lipocalin 
could be used on top of existing risk scores to further risk-stratify 
those at higher risk of postoperative acute kidney injury and 
1-year mortality.
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considered fit enough for major heart surgery, and therefore it 
is unlikely these confounders were present at the time.
cOnclusIOns
In a cohort of high-risk adult patients undergoing cardiac 
surgery, preoperative serum NGAL was an independent 
predictor of postoperative AKI and 1-year cardiovascular and 
all-cause mortality. Those in the third tertile of preoperative 
serum NGALpre-op (>220 ng/L) had a twofold increase risk of 
postoperative AKI and mortality at 1 year. The risk stratifica-
tion of patients prior to cardiac surgery may be improved by 
adding preoperative serum NGAL to existing risk scores for 
AKI and mortality and warrants further investigations.
Author affiliations
1National Heart Research Institute Singapore, National Heart Centre, Singapore, 
Singapore
2The Hatter Cardiovascular Institute, University College, London, UK
3Papworth Hospital, Cambridge, UK
4Centre for Quantitative Medicine Duke-NUS Medical School Academia, Singapore, 
Singapore
5Department of Medical Statistics, London School of Hygiene & Tropical Medicine, 
London, UK
6Barts Heart Centre, St Bartholomew’s Hospital, London, UK
7Anaesthetics, Intensive Care Medicine and Perioperative Pain Medicine, King’s 
College Hospital and King’s College London, London, UK
8The Royal Free Hospital, London, UK
9National Institute of Health Research Cardiovascular Biomedical Research Unit at 
Royal Brompton & Harefield National Health Service Trust, London, UK
10The National Institute of Health Research, University College London Hospitals, 
Biomedical Research Centre, London, UK
11Cardiovascular and Metabolic Disorders Program, Duke-National University of 
Singapore Medical School, Singapore, Singapore
12Yong Loo Lin School of Medicine, National University Singapore, Singapore, 
Singapore
contributors Conception this work: HB, LC, DMY and DJH. Acquisition of the data: 
LC, RE, DJ, SKM, GK, CL, JPM and DMY. Analysis and interpretation of the data: HB, 
RM, BC, JN, TC and DJH. Drafting of the manuscript: HB, RM, BC, LC and DJH. Critical 
review of the manuscript: CL, DMY, DJH, TC, LC, GK, DJ, JN, JPM, SKM and CL. Final 
approval of the version to be published: all authors. Guarantor of this work: DJH.
Funding The ERICCA study was supported by grants from the Efficacy and 
Mechanism Evaluation Program (a Medical Research Council and National 
Institute of Health Research partnership) (09/100/05) and the British Heart 
Foundation. Part of this work was supported by the National Institute for Health 
Research, University College London Hospitals, Biomedical Research Centre, 
the British Heart Foundation(FS/10/039/28270), Duke-National University 
Singapore Medical School, the Singapore Ministry of Health’s National Medical 
Research Council under its Clinician Scientist-Senior Investigator scheme 
(NMRC/CSA7SI/0011/2017) and Collaborative Centre Grant scheme (NMRC/
CGAug16C006) and the Singapore Ministry of Education Academic Research Fund 
Tier 2 (MOE20167T2727021).
competing interests None declared.
Patient consent Obtained.
ethics approval This study was approved by the National Health Service Research 
Ethics Committee, and all patients provided informed written consent.
Provenance and peer review Not commissioned; externally peer reviewed.
Open Access This is an Open Access article distributed in accordance with the 
terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others 
to distribute, remix, adapt and build upon this work, for commercial use, provided 
the original work is properly cited. See: http:// creativecommons. org/ licenses/ by/ 4. 0/
© Article author(s) (or their employer(s) unless otherwise stated in the text of the 
article) 2017. All rights reserved. No commercial use is permitted unless otherwise 
expressly granted.
reFerences
 1 Thiele RH, Isbell JM, Rosner MH, et al. AKI associated with cardiac surgery. Clin J Am 
Soc Nephrol 2015;10:500–14.
 2 Huen SC, Parikh CR. Predicting acute kidney injury after cardiac surgery: a systematic 
review, 2012. 1552-6259 (Electronic).
 3 Brown JR, Cochran RP, Dacey LJ, et al. Northern New England Cardiovascular Disease 
Study Group. Perioperative increases in serum creatinine are predictive of increased 
90-day mortality after coronary artery bypass graft surgery. Circulation 2006;114:I-
409–0.
 4 Koyner JL, Bennett MR, Worcester EM, et al. Urinary cystatin C as an early 
biomarker of acute kidney injury following adult cardiothoracic surgery. Kidney Int 
2008;74:1059–69.
 5 Hobson CE, Yavas S, Segal MS, et al. Acute kidney injury is associated with increased 
long-term mortality after cardiothoracic surgery. Circulation 2009;119:2444–53.
 6 Lassnigg A, Schmidlin D, Mouhieddine M, et al. Minimal changes of serum creatinine 
predict prognosis in patients after cardiothoracic surgery: a prospective cohort study. J 
Am Soc Nephrol 2004;15:1597–605.
 7 Lok CE, Austin PC, Wang H, et al. Impact of renal insufficiency on short- and long-
term outcomes after cardiac surgery. Am Heart J 2004;148:430–8.
 8 Chertow GM, Lazarus JM, Christiansen CL, et al. Preoperative renal risk stratification. 
Circulation 1997;95:878–84.
 9 Bhatt GC, Das RR. Early versus late initiation of renal replacement therapy in 
patients with acute kidney injury-a systematic review & meta-analysis of randomized 
controlled trials. BMC Nephrol 2017;18:78.
 10 Basile DP, Anderson MD, Sutton TA. Pathophysiology of acute kidney injury. Compr 
Physiol 2012;2:1303–53.
 11 Hvidberg V, Jacobsen C, Strong RK, et al. The endocytic receptor megalin binds the 
iron transporting neutrophil-gelatinase-associated lipocalin with high affinity and 
mediates its cellular uptake. FEBS Lett 2005;579:773–7.
 12 Haase M, Bellomo R, Devarajan P, et al.Accuracy of neutrophil gelatinase-associated 
lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: a systematic 
review and meta-analysis. Am J Kidney Dis 2009;54:1012–24.
 13 Devarajan P. Review: neutrophil gelatinase-associated lipocalin: a troponin-like 
biomarker for human acute kidney injury. Nephrology 2010;15:419–28.
 14 Mishra J, Mori K, Ma Q, et al. Neutrophil gelatinase-associated lipocalin: a novel early 
urinary biomarker for cisplatin nephrotoxicity. Am J Nephrol 2004;24:307–15.
 15 Mårtensson J, Bellomo R. The rise and fall of NGAL in acute kidney injury. Blood Purif 
2014;37:304–10.
 16 Moledina DG, Parikh CR, Garg AX, et al. TRIBE-AKI Consortium. Association of 
Perioperative plasma neutrophil Gelatinase-Associated lipocalin levels with 3-Year 
mortality after cardiac surgery: a prospective Observational Cohort Study. PLoS One 
2015;10:e0129619.
 17 Haase-Fielitz A, Bellomo R, Devarajan P, et al. Novel and conventional serum 
biomarkers predicting acute kidney injury in adult cardiac surgery--a prospective 
cohort study. Crit Care Med 2009;37:553–60.
 18 Doi K, Urata M, Katagiri D, et al. Plasma neutrophil gelatinase-associated lipocalin in 
acute kidney injury superimposed on chronic kidney disease after cardiac surgery: a 
multicenter prospective study. Crit Care 2013;17:R270.
 19 Hausenloy DJ, Candilio L, Laing C, et al.Effect of remote ischemic preconditioning 
on clinical outcomes in patients undergoing coronary artery bypass graft surgery 
(ERICCA): rationale and study design of a multi-centre randomized double-blinded 
controlled clinical trial. Clin Res Cardiol 2012;101:339–48.
 20 Hausenloy DJ, Candilio L, Evans R, et al.Remote ischemic preconditioning and 
outcomes of cardiac surgery. N Engl J Med 2015;373:1408–17.
 21 James M, Bouchard J, Ho J, et al. Canadian society of Nephrology commentary on 
the 2012 KDIGO clinical practice guideline for acute kidney injury. Am J Kidney Dis 
2013;61:673–85.
 22 Brown JR, Cochran RP, Leavitt BJ, et al.Multivariable prediction of renal insufficiency 
developing after cardiac surgery. Circulation 2007;116:I-139–0.
 23 Nashef SA, Roques F, Sharples LD, et al. EuroSCORE II. (1873-734X).
 24 Anderson RP. First publications from the Society of thoracic Surgeons National 
Database. Ann Thorac Surg 1994;57:6–7.
 25 Coca SG, Garg AX, Thiessen-Philbrook H, et al.Urinary biomarkers of AKI and mortality 
3 years after cardiac surgery. J Am Soc Nephrol 2014;25:1063–71.
 26 Lindberg S, Jensen JS, Mogelvang R, et al. Plasma neutrophil gelatinase-associated 
lipocalinin in the general population: association with inflammation and prognosis. 
Arterioscler Thromb Vasc Biol 2014;34:2135–42.
 27 Daniels LB, Barrett-Connor E, Clopton P, et al. Plasma neutrophil gelatinase-
associated lipocalin is independently associated with cardiovascular disease and 
mortality in community-dwelling older adults: the Rancho Bernardo Study. J Am Coll 
Cardiol 2012;59:1101–9.
group.bmj.com on January 26, 2018 - Published by http://heart.bmj.com/Downloaded from 
injury and mortality
kidneyprior to cardiac surgery predicts acute 
Neutrophil gelatinase-associated lipocalin
Yellon and Derek J Hausenloy
Kunst, Christopher Laing, Jennifer Nicholas, John Pepper, Derek M
Tim Clayton, Richard Evans, David P Jenkins, Shyam Kolvekar, Gudrun 
Heerajnarain Bulluck, Raju Maiti, Bibhas Chakraborty, Luciano Candilio,
 published online August 9, 2017Heart
 http://heart.bmj.com/content/early/2017/08/09/heartjnl-2017-311760
Updated information and services can be found at: 
These include:
References
 ef-list-1
http://heart.bmj.com/content/early/2017/08/09/heartjnl-2017-311760#r
This article cites 25 articles, 9 of which you can access for free at: 
Open Access
http://creativecommons.org/licenses/by/4.0/
use, provided the original work is properly cited. See: 
others to distribute, remix, adapt and build upon this work, for commercial
the Creative Commons Attribution (CC BY 4.0) license, which permits 
This is an Open Access article distributed in accordance with the terms of
service
Email alerting
box at the top right corner of the online article. 
Receive free email alerts when new articles cite this article. Sign up in the
Collections
Topic Articles on similar topics can be found in the following collections 
 (278)Open access
Notes
http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
http://journals.bmj.com/cgi/reprintform
To order reprints go to:
http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
group.bmj.com on January 26, 2018 - Published by http://heart.bmj.com/Downloaded from 
